Does Rallies show live market data for FDMT?

Rallies combines live market context with ticker research for FDMT, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

FDMT (4D Molecular Therapeutics, Inc. Common Stock) Stock Analysis

4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of May 21, 2026, FDMT trades at $8.49 with a market cap of $437.29M and a P/E ratio of -3.28. FDMT moved +0.89% today. Year to date, FDMT is +16.03%; over the trailing twelve months it is +120.00%. Its 52-week range spans $2.24 to $12.34. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest FDMT stock research?

4D Molecular Therapeutics, Inc. Common Stock (FDMT) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. FDMT moved +0.89% today. Analyst consensus is strong buy.

FDMT Key Metrics

Key financial metrics for FDMT
Metric	Value
Price	$8.49
Market Cap	$437.29M
P/E Ratio	-3.28
EPS	$-2.57
Dividend Yield	0.00%
52-Week High	$12.34
52-Week Low	$2.24
Volume	414.02K
Avg Volume	0
Revenue (TTM)	$88.24M
Net Income	$-160.90M
Gross Margin	0.00%

Latest FDMT News

4D Molecular Therapeutics Reports $458M Cash, Completes 523-Patient Phase 3 Enrollment — May 7, 2026
4D Molecular Therapeutics Posts $0.43 EPS, $85M Q4 Revenue Beat Expectations — Mar 19, 2026
4D Molecular Therapeutics Secures $514M Cash Runway, Otsuka $85M Deal — Mar 18, 2026
4D Molecular Therapeutics Completes Phase 3 Enrollment in 11 Months, Secures $33 Target — Feb 28, 2026
4D Molecular Therapeutics Grants 124,200 RSUs to Nine New Hires — Feb 13, 2026

Recent FDMT Insider Trades

Gupta Ashoo sold 310 (~$2.67K) on Mar 20, 2026.
Gupta Ashoo sold 80 (~$688.8) on Mar 20, 2026.
Gupta Ashoo sold 310 (~$2.69K) on Dec 20, 2025.

FDMT Analyst Consensus

9 analysts cover FDMT: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.00.

Common questions about FDMT

What can I research for FDMT on Rallies?: 4D Molecular Therapeutics, Inc. Common Stock (FDMT) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. FDMT moved +0.89% today. Analyst consensus is strong buy.
Does Rallies show live market data for FDMT?: Rallies combines live market context with ticker research for FDMT, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.